Amino Acid Formula With Vitamins And Minerals Without Methionine, Threonine And Valine And Low In Isoleucine
Dietary management of patients with a proven diagnosis of methylmalonic acidaemia (MMA) or propionic acidaemia (PA).
Decision on record
- Meeting Nov 2024 Recommended Methylmalonic acidaemia; propionic acidaemia
Access path
- Nov 2015Recommended · restricted
vs MMA/PA Gel® and XMTVI Maxamaid®
- Nov 2024Recommended · restricted
Comparator changed: MMA/PA Gel® and XMTVI Maxamaid® → MMA/PA Anamix Junior and MMA/PA…
- PBS listing · Restricted
From the public summary
7.1 The PBAC recommended a General Schedule Restricted Benefit listing of amino acid formula with vitamins and minerals without methionine, threonine and valine and low in isoleucine, sachets containing oral powder 12.5 g, 30 (MMA/PA explore5™) for the dietary management of patients with a proven diagnosis of methylmalonic acidaemia (MMA) or propionic acidaemia (PA), under the same circumstances as the current listings for MMA/PA Anamix Junior and MMA/PA …PSD · Nov 2024
7.2 The PBAC considered that MMA/PA explore5 should be cost-minimised to the lowest cost comparator accepted by the NPWP (i.e., MMA/PA Anamix Junior and MMA/PA Anamix Infant) at an equivalent price per gram of protein equivalent.PSD · Nov 2024
5.9 The submission presented a cost-minimisation analysis of MMA/PA explore5 compared to MMA/PA Anamix Junior, based on the same cost per gram of PE. While MMA/PA Anamix Infant is also a main comparator, it was excluded from the economic analysis as the submission claimed MMA/PA Anamix Infant is an infant protein substitute whereas MMA/PA explore5 and MMA/PA Anamix Junior are ‘second-stage’ protein substitutes.PSD · Nov 2024
5.10 The protein equivalent content and proposed price of MMA/PA explore5, in comparison to MMA/PA Anamix Junior, are outlined in Table 2.PSD · Nov 2024
5.8 The submission claimed that MMA/PA explore5 is therapeutically comparable to MMA/PA Anamix Junior and MMA/PA Anamix Infant.PSD · Nov 2024
Cost-effectiveness
Cost-minimisation analysis; no ICER calculated by design.
The PBAC considered that MMA/PA explore5 should be cost-minimised to the lowest cost comparator accepted by the NPWP (i.e., MMA/PA Anamix Junior and MMA/PA Anamix Infant) at an equivalent price per gram of protein equivalent. PBAC · 2024
Decision context
PopulationInfants and children aged six months to five years with a proven diagnosis of methylmalonic acidaemia (MMA) or propionic acidaemia (PA).
Submission history
| Decided | Outcome | Comparator | ICER | Evidence |
|---|---|---|---|---|
| Nov 2024 | Recommended · restricted | MMA/PA Anamix Junior and MMA/PA Anamix Infant | — | Cost-minimisation · Cost-minimisation |
| Nov 2015 | Recommended · restricted | MMA/PA Gel® and XMTVI Maxamaid® | — | Cost-minimisation · Cost-minimisation |
Consumer voice
No consumer comments were received for this item.
The PBAC noted that no consumer comments were received for this item. Consumer comments · PSD
Similar precedents
Listed in law
PBS listings commencing 1 Apr 2025 were made by these 3 determinations under the National Health Act 1953. A determination covers every listing that commenced that day, so this is the legal instrument in force for the date — not a document naming this medicine. Open it and check.
| Determination | Made | Status | |
|---|---|---|---|
| PB 24 of 2025 | 27 Mar 2025 | Repealed | PDF ↗ |
| PB 25 of 2025 | 27 Mar 2025 | Repealed | PDF ↗ |
| PB 26 of 2025 | 27 Mar 2025 | Repealed | PDF ↗ |